{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:45:14Z","timestamp":1791233114086,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100009895","name":"Canc\u00e9rop\u00f4le Grand Ouest","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009895","id-type":"DOI","asserted-by":"publisher"}]},{"name":"D\u00e9fi Cl\u00e9 Cell-Based Biotherapies Occitanie (CeBBOc) CoPoC funding from Inserm Transfert grant"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1038\/s41417-025-00984-8","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T05:28:37Z","timestamp":1761802117000},"page":"76-84","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Bacterial nanoparticles as a potent and safe alternative to BCG for bladder cancer immunotherapy"],"prefix":"10.1038","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-8778-0885","authenticated-orcid":false,"given":"Marine","family":"Colson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4344-1194","authenticated-orcid":false,"given":"Arthur","family":"Aubry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Gaide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Lluel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Oswald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0339-4941","authenticated-orcid":false,"given":"Laure","family":"David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"984_CR1","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41571-023-00744-3","volume":"20","author":"LMC Van Hoogstraten","year":"2023","unstructured":"Van Hoogstraten LMC, Vrieling A, Van Der Heijden AG, Kogevinas M, Richters A, Kiemeney LA. Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice. Nat Rev Clin Oncol. 2023;20:287\u2013304.","journal-title":"Nat Rev Clin Oncol"},{"key":"984_CR2","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"984_CR3","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"984_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1170124","volume":"13","author":"K Grabe-Heyne","year":"2023","unstructured":"Grabe-Heyne K, Henne C, Mariappan P, Geiges G, P\u00f6hlmann J, Pollock RF. Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs. Front Oncol. 2023;13:1170124.","journal-title":"Front Oncol"},{"key":"984_CR5","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2147\/CEOR.S274951","volume":"12","author":"LJ Lee","year":"2020","unstructured":"Lee LJ, Kwon CS, Forsythe A, Mamolo CM, Masters ET, Jacobs IA. Humanistic and economic burden of non-muscle invasive bladder cancer: results of two systematic literature reviews. CEOR. 2020;12:693\u2013709.","journal-title":"CEOR"},{"key":"984_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcpo.2022.100326","volume":"32","author":"JC Michaeli","year":"2022","unstructured":"Michaeli JC, Boch T, Albers S, Michaeli T, Michaeli DT. Socio-economic burden of disease: survivorship costs for bladder cancer. J Cancer Policy. 2022;32:100326.","journal-title":"J Cancer Policy"},{"key":"984_CR7","doi-asserted-by":"crossref","unstructured":"Gontero P, Birtle A, Capoun O, Comp\u00e9rat E, Dominguez-Escrig JL, Liedberg F, et al. European Association of Urology guidelines on non\u2013muscle-invasive bladder cancer (TaT1 and carcinoma in situ)\u2014a summary of the 2024 guidelines update. European Urology. 2024;86:531\u201349.","DOI":"10.1016\/j.eururo.2024.07.027"},{"key":"984_CR8","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1097\/JU.0000000000003846","volume":"211","author":"JM Holzbeierlein","year":"2024","unstructured":"Holzbeierlein JM, Bixler BR, Buckley DI, Chang SS, Holmes R, James AC, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline: 2024 amendment. J Urol. 2024;211:533\u20138.","journal-title":"J Urol"},{"key":"984_CR9","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.3390\/cancers16101843","volume":"16","author":"S McNall","year":"2024","unstructured":"McNall S, Hooper K, Sullivan T, Rieger-Christ K, Clements M. Treatment modalities for non-muscle invasive bladder cancer: an updated review. Cancers. 2024;16:1843.","journal-title":"Cancers"},{"key":"984_CR10","doi-asserted-by":"publisher","first-page":"539","DOI":"10.3390\/biomedicines11020539","volume":"11","author":"Y Shi","year":"2023","unstructured":"Shi Y, Mathis BJ, He Y, Yang X. The current progress and future options of multiple therapy and potential biomarkers for muscle-invasive bladder cancer. Biomedicines. 2023;11:539.","journal-title":"Biomedicines"},{"key":"984_CR11","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk M, Burger M, Capoun O, Cohen D, Comp\u00e9rat EM, Dominguez Escrig JL, et al. European Association of Urology guidelines on non\u2013muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol. 2022;81:75\u201394.","journal-title":"Eur Urol"},{"key":"984_CR12","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrurol.2014.15","volume":"11","author":"G Redelman-Sidi","year":"2014","unstructured":"Redelman-Sidi G, Glickman MS, Bochner BH. The mechanism of action of BCG therapy for bladder cancer\u2014a current perspective. Nat Rev Urol. 2014;11:153\u201362.","journal-title":"Nat Rev Urol"},{"key":"984_CR13","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0022-5347(17)42445-1","volume":"139","author":"TL Ratliff","year":"1988","unstructured":"Ratliff TL, Kavoussi LR, Catalona WJ. Role of fibronectin in intravesical BCG therapy for superficial bladder cancer. J Urol. 1988;139:410\u20134.","journal-title":"J Urol"},{"key":"984_CR14","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1158\/1055-9965.EPI-19-1534","volume":"29","author":"AB Mariotto","year":"2020","unstructured":"Mariotto AB, Enewold L, Zhao J, Zeruto CA, Yabroff KR. Medical care costs associated with cancer survivorship in the United States. Cancer Epidemiol, Biomark Prev. 2020;29:1304\u201312.","journal-title":"Cancer Epidemiol, Biomark Prev"},{"key":"984_CR15","doi-asserted-by":"crossref","unstructured":"Kamel MH, Bailey SL, Moore JT, Heshmat SM, Bissada NK. Definition of BCG failure in non-muscle invasive bladder cancer in major urological guidelines. UIJ. 2011;04. Available from: http:\/\/www.urotoday.com\/index.php?option=com_content&catid=1182&id=48720&lang=en&view=article&Itemid=0.","DOI":"10.3834\/uij.1944-5784.2011.12.15"},{"key":"984_CR16","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.acuro.2024.01.008","volume":"48","author":"F Guerrero-Ramos","year":"2024","unstructured":"Guerrero-Ramos F, \u00c1lvarez-Maestro M, Pinto Mar\u00edn \u00c1, Dom\u00ednguez Escrig JL, Rodr\u00edguez Faba \u00d3. Multidisciplinary consensus document on the current treatment of bacille Calmette-Gu\u00e9rin-unresponsive non-muscle invasive bladder tumor. Actas Urol\u00f3gicas Espa\u00f1olas. 2024;48:262\u201372.","journal-title":"Actas Urol\u00f3gicas Espa\u00f1olas"},{"key":"984_CR17","doi-asserted-by":"crossref","unstructured":"D\u2019Andrea D, Mostafid H, Gontero P, Shariat S, Kamat A, Masson-Lecomte A, et al. Unmet need in non\u2013muscle-invasive bladder cancer failing Bacillus Calmette-Gu\u00e9rin therapy: a systematic review and cost-effectiveness analyses from the International Bladder Cancer Group. Eur Urol Oncol. 2024;8:216\u201329.","DOI":"10.1016\/j.euo.2024.10.012"},{"key":"984_CR18","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s40259-023-00627-0","volume":"38","author":"F Micoli","year":"2024","unstructured":"Micoli F, Adamo R, Nakakana U. Outer membrane vesicle vaccine platforms. BioDrugs. 2024;38:47\u201359.","journal-title":"BioDrugs"},{"key":"984_CR19","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/s41551-022-00886-2","volume":"6","author":"Y Yue","year":"2022","unstructured":"Yue Y, Xu J, Li Y, Cheng K, Feng Q, Ma X, et al. Antigen-bearing outer membrane vesicles as tumour vaccines produced in situ by ingested genetically engineered bacteria. Nat Biomed Eng. 2022;6:898\u2013909.","journal-title":"Nat Biomed Eng"},{"key":"984_CR20","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2024.2341670","volume":"16","author":"CV Olovo","year":"2024","unstructured":"Olovo CV, Wiredu Ocansey DK, Ji Y, Huang X, Xu M. Bacterial membrane vesicles in the pathogenesis and treatment of inflammatory bowel disease. Gut Microbes. 2024;16:2341670.","journal-title":"Gut Microbes"},{"key":"984_CR21","doi-asserted-by":"publisher","first-page":"3328","DOI":"10.3390\/cancers15133328","volume":"15","author":"E Caproni","year":"2023","unstructured":"Caproni E, Corbellari R, Tomasi M, Isaac SJ, Tamburini S, Zanella I, et al. Anti-tumor efficacy of in situ vaccination using bacterial outer membrane vesicles. Cancers. 2023;15:3328.","journal-title":"Cancers"},{"key":"984_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpha.2024.101049","volume":"14","author":"S Xiang","year":"2024","unstructured":"Xiang S, Khan A, Yao Q, Wang D. Recent advances in bacterial outer membrane vesicles: Effects on the immune system, mechanisms and their usage for tumor treatment. J Pharm Anal. 2024;14:101049.","journal-title":"J Pharm Anal"},{"key":"984_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2020.100924","volume":"76","author":"KP Downs","year":"2020","unstructured":"Downs KP, Nguyen H, Dorfleutner A, Stehlik C. An overview of the non-canonical inflammasome. Mol Asp Med. 2020;76:100924.","journal-title":"Mol Asp Med"},{"key":"984_CR24","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.tim.2021.04.003","volume":"29","author":"S Dhital","year":"2021","unstructured":"Dhital S, Deo P, Stuart I, Naderer T. Bacterial outer membrane vesicles and host cell death signaling. Trends Microbiol. 2021;29:1106\u201316.","journal-title":"Trends Microbiol"},{"key":"984_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00729-8","volume":"8","author":"OY Kim","year":"2017","unstructured":"Kim OY, Park HT, Dinh NTH, Choi SJ, Lee J, Kim JH, et al. Bacterial outer membrane vesicles suppress tumor by interferon-\u03b3-mediated antitumor response. Nat Commun. 2017;8:626.","journal-title":"Nat Commun"},{"key":"984_CR26","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1093\/infdis\/jiv506","volume":"213","author":"K Murase","year":"2016","unstructured":"Murase K, Martin P, Porcheron G, Houle S, Helloin E, P\u00e9nary M, et al. HlyF produced by extraintestinal pathogenic Escherichia coli is a virulence factor that regulates outer membrane vesicle biogenesis. J Infect Dis. 2016;213:856\u201365.","journal-title":"J Infect Dis"},{"key":"984_CR27","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1080\/15548627.2022.2054040","volume":"18","author":"L David","year":"2022","unstructured":"David L, Taieb F, P\u00e9nary M, Bordignon PJ, Plan\u00e8s R, Bagayoko S, et al. Outer membrane vesicles produced by pathogenic strains of Escherichia coli block autophagic flux and exacerbate inflammasome activation. Autophagy. 2022;18:2913\u201325.","journal-title":"Autophagy"},{"key":"984_CR28","doi-asserted-by":"crossref","unstructured":"Lin JF, Hwang TIS. Autophagy regulation in bladder cancer as the novel therapeutic strategy. Transl Cancer Res. 2017;6. Available from: https:\/\/tcr.amegroups.org\/article\/view\/14110.","DOI":"10.21037\/tcr.2017.06.26"},{"key":"984_CR29","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1158\/2159-8290.CD-18-0044","volume":"8","author":"B Olson","year":"2018","unstructured":"Olson B, Li Y, Lin Y, Liu ET, Patnaik A. Mouse models for cancer immunotherapy research. Cancer Discov. 2018;8:1358\u201365.","journal-title":"Cancer Discov"},{"key":"984_CR30","doi-asserted-by":"publisher","first-page":"4118","DOI":"10.3390\/ijms21114118","volume":"21","author":"DS Chulpanova","year":"2020","unstructured":"Chulpanova DS, Kitaeva KV, Rutland CS, Rizvanov AA, Solovyeva VV. Mouse tumor models for advanced cancer immunotherapy. IJMS. 2020;21:4118.","journal-title":"IJMS"},{"key":"984_CR31","doi-asserted-by":"publisher","first-page":"108631","DOI":"10.1016\/j.pharmthera.2024.108631","volume":"257","author":"SM Stribbling","year":"2024","unstructured":"Stribbling SM, Beach C, Ryan AJ. Orthotopic and metastatic tumour models in preclinical cancer research. Pharmacol Therapeutics. 2024;257:108631.","journal-title":"Pharmacol Therapeutics"},{"key":"984_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.70032","volume":"14","author":"A Goman","year":"2025","unstructured":"Goman A, Ize B, Jeannot K, Pin C, Payros D, Goursat C, et al. Uncovering a new family of conserved virulence factors that promote the production of host-damaging outer membrane vesicles in gram-negative bacteria. J Extracell Vesicle. 2025;14:e270032.","journal-title":"J Extracell Vesicle"},{"key":"984_CR33","unstructured":"Kumar R. Basic pathology. 2022. Available from: https:\/\/shop.elsevier.com\/books\/robbins-and-kumar-basic-pathology\/kumar\/978-0-323-79018-5."},{"key":"984_CR34","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"984_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/9634902","volume":"2018","author":"J Falke","year":"2018","unstructured":"Falke J, Parkkinen J, Vaahtera L, Hulsbergen-van De Kaa CA, Oosterwijk E, Witjes JA. Curcumin as treatment for bladder cancer: a preclinical study of cyclodextrin-curcumin complex and BCG as intravesical treatment in an orthotopic bladder cancer rat model. BioMed Res Int. 2018;2018:1\u20137.","journal-title":"BioMed Res Int"},{"key":"984_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.1029146","volume":"13","author":"LA Lieberman","year":"2022","unstructured":"Lieberman LA. Outer membrane vesicles: a bacterial-derived vaccination system. Front Microbiol. 2022;13:1029146.","journal-title":"Front Microbiol"},{"key":"984_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2023.102376","volume":"84","author":"P Van Der Ley","year":"2023","unstructured":"Van Der Ley P, Schijns VE. Outer membrane vesicle-based intranasal vaccines. Curr Opin Immunol. 2023;84:102376.","journal-title":"Curr Opin Immunol"},{"key":"984_CR38","doi-asserted-by":"publisher","first-page":"e11334","DOI":"10.1371\/journal.pone.0011334","volume":"5","author":"KS Park","year":"2010","unstructured":"Park KS, Choi KH, Kim YS, Hong BS, Kim OY, Kim JH, et al. Outer membrane vesicles derived from Escherichia coli induce systemic inflammatory response syndrome. PLoS One. 2010;5:e11334.","journal-title":"PLoS One"},{"key":"984_CR39","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf9419","volume":"375","author":"TN Schumacher","year":"2022","unstructured":"Schumacher TN, Thommen DS. Tertiary lymphoid structures in cancer. Science. 2022;375:eabf9419.","journal-title":"Science"},{"key":"984_CR40","unstructured":"Gulinac M, Dikov D, Lichev S, Velikova T. Current concept for tertiary lymphoid structures in urothelial carcinoma of the bladder: a literature review and our experience. Am J Clin Exp Immunol. 2020;9:64\u201372."},{"key":"984_CR41","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41392-024-01947-5","volume":"9","author":"L Zhao","year":"2024","unstructured":"Zhao L, Jin S, Wang S, Zhang Z, Wang X, Chen Z, et al. Tertiary lymphoid structures in diseases: immune mechanisms and therapeutic advances. Sig Transduct Target Ther. 2024;9:225.","journal-title":"Sig Transduct Target Ther"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00984-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00984-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00984-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T23:01:59Z","timestamp":1768172519000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00984-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["984"],"URL":"https:\/\/doi.org\/10.1038\/s41417-025-00984-8","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]},"assertion":[{"value":"24 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}